You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The European Commission recently awarded the company a two-year, €2.6 million Horizon 2020 grant to achieve its ambitions.
Other grant recipients include scientists from the University of Chicago, UCLA, UC Santa Barbara, and the University of Washington.
The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
The test will be designed to run on a portable device that can ultimately be rolled out to point-of-need settings such as doctors' offices and workplaces.
A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.
Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.